3Ghannoum MA, Long L, Pfister WR. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of der- matophytosis in a guinea pig model [ J ]. Mycoses, 2009,52 ( 1 ) : 35- 43.
4Elewski BE, Ghannoum MA, Mayser P, et al. Efficacy, safety and tol- erability of topical terbinafine nail solution in patients with mild-to- moderate toenail onychomycosis:results from three randomized stud- ies using double-blind vehicle-controlled and open-label active-con- trolled designs[ J J. J Eur Acad Dermatol Venerol, 2011, [ Epub a- head of printS. Ghannoum M, Isham N, Herbert J, et al. Activity of TDT 067 ( terbin- afine in Transfersome ).
5against agents of onychomycosis, as deter- mined by minimum inhibitory and fungicidal concentrations [ J ]. J CIin Microbiol, 2011,49(5) :1715-1720.
6Pannu J, McCarthy A, Martin A, et al. NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamen- tous fungi, and Candida albicans[ J ] Antimicrob Agents Chemother, 2009,53 ( 8 ) :3273-3279.
7Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomyeosis. Two phase IIl multieenter, randomized,double-blindstudies[ J]. J Ami Acad Dermatol,2012,20 (12) :1140-1141.
8Gupta AK,Simpson FC. New therapeutic options for onychomycosis. Expert opinion on pharmacotherapy [ J ]. June, 2012,13 ( 8 ) : 1131- 1142.
9Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site[ J]. Science ,2007,316 (5832) :1759-1761.
10Hui X, Baker SJ, Wester RC, et al. In Vitro penetration of a novel ox- aborole antifungal(AN2690) into the human nail plate[ J ]. J Pharm Sci ,2007,96(10) :2622-2631.
4Tanuma H. Current topics in diagnosis and treatment of tinea unguium in Japan. J Dermatol 1999;26:87 - 97.
5Syed TA, Ahmadpour OA, Ahmad SA, et al.Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo- controlled, double - blind study. J Dermatol 1998;25:648 - 652.
6Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatmeat of onychomycosis. J Am Acad Dermatol 2000;43:57 - 69.
7Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43:70- 80.
8Kwok YK, Tay YK, Goh CL, et al. Epidemiology and in vitro activity of antimycotics against candidal vaginal/skin/nail infections in Singapore. Int J Dermatol 1998; 37:145 -149.
9Elewski BE. Onychomycosis: pathogenesis,diagnsis and management. Clin Microbiol Rev 1998; 11:415 - 429.
10Baran R, Hay R J, Tosti A, et al. A new classification of onychomycosis. British Journal of dermatology 1998;139:567-571.
7Thomas J, Jacobson GA, Narkowicz CK,et al. Toenail onychomycosis: an important global disease burden [J].J Clin Pharm Ther,2010,35(5):497- 519.
8Piraccini B,Sisti A,Tosti A.Long-term follow-up of toenail onychomycosis caused by dermatophytes atter successful treatment with systemic antifungal agents [J]. J Am AcadDermatol,2010, 62:411-414.
9Bomstein E,Hermans W, Gridley S,et al.Near-infrared photoinactivation of bacteria and fungi at physiologic temperatures[J].Photochem Photobiol,2009,85:1364-1374.
10Shaymaa Muhammad Ally Essayed,Mohammad Ahmad alShatouri,Yasser Salem Nasr Allah,et al.Ultrasonographic characterization of the nails in patients with psoriasis and onychomycosis[J].The Egyptian Journal of Radiology and Nuclear Medicine,2015,4(9):63-65.
